Swiss biotech company DBS System has just closed a round of €2.3 million in Series A financing. The investment was led by investiere.ch. Existing shareholders and private business angels of DBS System also participated in the round.
DBS System produces blood collection devices using advanced microfluidic technology, which simplifies and reduces the cost of blood sampling. With this investment, DBS System will produce its second generation HemaXis™ blood collection device that passively separates plasma or serum from whole blood, thus increasing the range of tests that can be run on dried blood spot samples by certified laboratories.
The company aims to establish itself as the leading manufacturer devices for collecting and preparing micro samples of blood. DBS System is already producing and selling its first-generation device, HemaXis DB, for whole blood collection, and is establishing partnerships with major labs in Europe and the US.
“The advantages of our technology are clear: the device can be used by anyone in a non-medical environment, blood samples are reliable, secured and standardized, logistics are simplified, and it fits within the existing workflow, all together resulting in significant cost savings for labs” said CEO Eric Ödman in a statement. “This model is beneficial for us and our partners because they can expand their market by reaching more patients and it enables us to leverage them to build awareness and prescribe the use of our devices through their distribution networks in an estimated addressable market size of USD 20 Billion”.
Read more: PR Underground (Press release)